Payment overview · 2025
General Payments
$719.56
57 reported records · 11 companies
Healthcare provider profile · identity verified
Bryan Hammar, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · RIGBY, ID · NPI 1841219987
Verified facts
What the public records show
CMS Open Payments records show Bryan Hammar, D.O. received $719.56 in general payments during 2025 across 57 reported records.
ABBVIE INC. accounted for 44.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $322.40 | 44.8% | 24 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $145.42 | 20.2% | 16 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $62.01 | 8.6% | 3 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $40.34 | 5.6% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $36.44 | 5.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.18 | 3.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $27.99 | 3.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.07 | 2.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.70 | 2.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.60 | 1.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.41 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $719.56 | 57 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $171.14 | 12 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $145.42 | 16 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $140.27 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $137.29 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $76.19 | 7 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $62.01 | 3 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $40.34 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $36.44 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.18 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.18 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $27.99 | 2 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $15.73 | 2 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $15.07 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 62 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
62 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 487 | 118 |
| Levothyroxine Sodium | Levothyroxine Sodium | 468 | 118 |
| Losartan Potassium | Losartan Potassium | 356 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 342 | 88 |
| Atorvastatin Calcium | Atorvastatin Calcium | 329 | 82 |
| Gabapentin | Gabapentin | 310 | 78 |
| Metformin Hcl | Metformin Hcl | 283 | 65 |
| Lisinopril | Lisinopril | 260 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 233 | 63 |
| Potassium Chloride | Potassium Chloride | 229 | 71 |
| Simvastatin | Simvastatin | 217 | 54 |
| Furosemide | Furosemide | 211 | 69 |
| Lorazepam | Lorazepam | 205 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 200 | 53 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 198 | 45 |
| Tramadol Hcl | Tramadol Hcl | 190 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 178 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 177 | 56 |
| Duloxetine Hcl | Duloxetine Hcl | 163 | 30 |
| Sertraline Hcl | Sertraline Hcl | 163 | 37 |
| Trazodone Hcl | Trazodone Hcl | 163 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 155 | 46 |
| Metformin Hcl Er | Metformin Hcl | 153 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 149 | 29 |
| Bupropion Xl | Bupropion Hcl | 148 | 36 |
| Alprazolam | Alprazolam | 142 | 28 |
| Montelukast Sodium | Montelukast Sodium | 126 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 120 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 117 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 116 | 35 |
| Allopurinol | Allopurinol | 116 | 35 |
| Famotidine | Famotidine | 116 | 29 |
| Clonazepam | Clonazepam | 114 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 98 | 27 |
| Carvedilol | Carvedilol | 95 | 28 |
| Lovastatin | Lovastatin | 95 | 27 |
| Glimepiride | Glimepiride | 94 | 21 |
| Farxiga | Dapagliflozin Propanediol | 92 | 17 |
| Eliquis | Apixaban | 90 | 17 |
| Meloxicam | Meloxicam | 88 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 20 |
| Telmisartan | Telmisartan | 83 | 22 |
| Finasteride | Finasteride | 75 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 74 | 12 |
| Ezetimibe | Ezetimibe | 72 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 69 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 68 | 22 |
| Ibuprofen | Ibuprofen | 65 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 64 | 13 |
| Mounjaro | Tirzepatide | 62 | 13 |
| Clonidine Hcl | Clonidine Hcl | 60 | 18 |
| Pregabalin | Pregabalin | 56 | 17 |
| Alendronate Sodium | Alendronate Sodium | 55 | 15 |
| Olanzapine | Olanzapine | 53 | suppressed |
| Ozempic | Semaglutide | 53 | 13 |
| Aripiprazole | Aripiprazole | 51 | suppressed |
| Celecoxib | Celecoxib | 51 | 21 |
| Diazepam | Diazepam | 51 | 11 |
| Januvia | Sitagliptin Phosphate | 51 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 51 | 17 |
| Atenolol | Atenolol | 50 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | 11 |
| Cephalexin | Cephalexin | 48 | 26 |
| Estradiol | Estradiol | 48 | 17 |
| Risperidone | Risperidone | 48 | 11 |
| Spironolactone | Spironolactone | 48 | 16 |
| Prednisone | Prednisone | 46 | 23 |
| Testosterone Cypionate | Testosterone Cypionate | 45 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 44 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 43 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 42 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | 15 |
| Memantine Hcl | Memantine Hcl | 41 | suppressed |
| Jardiance | Empagliflozin | 40 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 40 | suppressed |
| Topiramate | Topiramate | 40 | 11 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 38 | 12 |
| Ziprasidone Hcl | Ziprasidone Hcl | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 14 |
| Lansoprazole | Lansoprazole | 36 | suppressed |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Azithromycin | Azithromycin | 35 | 25 |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 33 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 30 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | suppressed |
| Sotalol | Sotalol Hcl | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 24 | suppressed |
| Invokana | Canagliflozin | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Carisoprodol | Carisoprodol | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 14 |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Cholestyramine Light | Cholestyramine | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Dexamethasone | Dexamethasone | 15 | 13 |
| Fluconazole | Fluconazole | 15 | 12 |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $719.56 · 57 records | ABBVIE INC. | Auvelity, Azstarys, CAPLYTA, COSENTYX, ENBREL, FANAPT, MOUNJARO, OTEZLA, QULIPTA, REPATHA, REXULTI, UBRELVY, VOQUEZNA, VRAYLAR, XIFAXAN, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error